Cannabis does appear to help migraines for a majority of people who try it, though the evidence comes mostly from observational studies rather than large randomized trials. In a cross-sectional study of 145 medical cannabis patients with migraines, 61% experienced at least a 50% reduction in monthly migraine frequency. A separate large retrospective analysis of over 7,400 cannabis sessions for migraine found a nearly 50% decrease in migraine severity ratings after use. These are promising numbers, but cannabis also carries real risks for migraine sufferers, including a strong association with rebound headaches.
Why Cannabis Might Work for Migraines
Your body produces its own cannabis-like molecules called endocannabinoids. These molecules help regulate pain signaling, inflammation, and the balance between excitatory and calming activity in the brain. One theory, proposed by neurologist Ethan Russo in 2006, suggests that people with migraines may have a deficiency in this system.
Several studies support that idea. People with chronic migraines have lower levels of these natural molecules in both their blood platelets and spinal fluid compared to healthy controls. Brain imaging studies have also found changes in cannabinoid receptor activity in pain-processing areas of the brain in women with migraines, suggesting the body is trying to compensate for something missing. In animal models, the endocannabinoid anandamide directly reduces excitability in the trigeminovascular system, the main nerve network involved in a migraine attack.
When you use cannabis, THC and CBD interact with this same system. THC activates the receptors directly, while CBD influences them more indirectly. The result, at least in theory, is that cannabis may be filling a gap that the body’s own system can’t cover on its own.
What the Clinical Numbers Show
The strongest signal comes from a Colorado analysis of 121 adults with migraines. Their average migraine frequency dropped from 10.4 to 4.6 attacks per month after starting cannabis, a reduction of more than 55%. Patients who responded well to treatment also reported less migraine-related disability in daily life and lower use of other migraine medications, including triptans and opioids.
For acute attacks, inhaled cannabis flower showed particularly fast results. In a large retrospective study analyzing nearly 2,000 sessions, 94% of participants reported symptom relief within two hours. That speed is comparable to many standard migraine medications, though direct head-to-head comparisons remain limited.
One small trial did compare a THC-CBD combination (200 mg daily) against amitriptyline, a commonly prescribed migraine preventive, over three months in chronic migraine patients. The cannabis combination showed a 40.4% improvement, essentially matching amitriptyline’s 40.1%. The cannabis group also used the same formulation to treat breakthrough attacks.
How Delivery Method Matters
The way you consume cannabis changes how quickly it works and how long the effects last, which matters depending on whether you’re trying to stop an attack in progress or prevent one from happening.
Inhaled cannabis (smoking or vaping) and sublingual products (oils or tinctures held under the tongue) have shorter onset times, typically within minutes. This makes them better suited for acute migraine attacks when you need fast relief. Edibles and oral capsules take longer to kick in, sometimes 30 to 90 minutes, but their effects last longer. That extended duration may make oral forms more useful for daily preventive use in chronic migraine.
Edibles do come with a specific caution. When THC passes through the liver, it converts into a more potent metabolite. This is why edibles tend to cause more drowsiness than inhaled cannabis, and why the effects can feel stronger and less predictable.
THC, CBD, and Terpenes
The ratio of THC to CBD in a cannabis product likely matters, though the research is still sorting out the ideal balance. A recent mouse study found that a CBD-heavy ratio (100 parts CBD to 1 part THC) reduced light sensitivity and facial pain responses across multiple migraine models. That’s notable because it suggests CBD-dominant products could offer migraine relief with minimal psychoactive effects.
On the other hand, migraine patients in a large survey most commonly preferred hybrid strains with high THC and low CBD content. The most popular strain across migraine and headache groups was “OG Shark,” which is THC-dominant and rich in two terpenes: beta-caryophyllene (also found in black pepper and cloves) and beta-myrcene (found in hops and lemongrass). Both terpenes have documented anti-inflammatory and pain-relieving properties. Beta-caryophyllene is unusual among terpenes because it directly activates one of the body’s cannabinoid receptors, essentially acting like a mild cannabinoid itself.
This doesn’t mean one specific strain is the answer. But it does suggest that the full chemical profile of a cannabis product, not just its THC or CBD content, influences how well it works for migraines.
The Rebound Headache Problem
This is the most important risk to understand. Medication overuse headache (MOH) happens when frequent use of a pain-relieving substance actually starts causing more headaches. It’s a well-known problem with triptans, over-the-counter painkillers, and opioids. Cannabis is not exempt.
A study of patients with chronic migraine found that 81% of current cannabis users met criteria for medication overuse headache, compared to 41% of those not using cannabis. After adjusting for other factors, cannabis use was associated with a sixfold increase in the odds of developing rebound headaches. That’s a comparable association to opioid use, which had a similarly strong link to MOH in the same study.
This doesn’t mean cannabis causes rebound headaches in everyone, but it does mean that frequent, escalating use for migraine carries a real risk of making the overall pattern worse.
Common Side Effects
The side effects most reported in medical cannabis studies for migraine include dizziness, dry mouth, dry eyes, nausea, drowsiness, and, in rare cases, psychosis. Drowsiness is especially common with edibles. Most of these are mild and dose-dependent, meaning they get worse at higher doses and improve when the dose is reduced.
The roughly 39% of patients in the cross-sectional study who didn’t achieve a meaningful reduction in migraine frequency are also worth noting. Cannabis is not a universal solution. Some people don’t respond, and the reasons likely involve individual differences in genetics, endocannabinoid system function, and migraine subtype.
Where the Evidence Stands
Most of the data on cannabis and migraines comes from retrospective analyses, cross-sectional surveys, and observational studies. These can identify patterns and associations, but they can’t prove cause and effect the way a double-blind randomized trial can. Placebo effects are hard to rule out with cannabis because users typically know whether they’ve consumed it.
The biological rationale is strong. The endocannabinoid deficiency theory has consistent support across blood, spinal fluid, and brain imaging studies. The clinical results are encouraging, with more than half of treated patients seeing meaningful improvement. But the rebound headache data is a genuine concern, particularly for people with chronic migraine who might use cannabis frequently. The most reasonable takeaway is that cannabis can be an effective tool for migraines, but it works best when used deliberately and not as an everyday default for every headache.